Efficacy and Safety of Lingzhi in Patients With Early Parkinson's Disease

Inclusion Criteria: willing and able to give informed consent age 30 years or older at time of diagnosis of Parkinson's disease have idiopathic Parkinson's disease, defined as: having at least 2 of the following 4 signs: resting tremor, bradykinesia, rigidity, or postural reflex impairment, at least one of which must be resting tremor or bradykinesia no secondary or atypical parkinsonism asymmetric features (current signs or history of asymmetric onset) response to L-dopa, by patient self-report Parkinson's disease duration of no more than 5 years receiving stable therapy of L-dopa/DCI for at least 3 months; acceptable dose range: 250 mg - 1000 mg L-dopa/DCI daily Hoehn and Yahr stage < 4 on stable L-dopa/DCI treatment Exclusion Criteria: have atypical parkinsonism due to drugs, metabolic disorders, encephalitis, or other neurodegenerative diseases have any other known medical or psychiatric condition that may compromise their participation in the study have taken another investigational drug within 90 days of baseline have a change in dosage of any other antiparkinsonian drug (eg, pramipexole, ropinirole, pergolide, bromocriptine, methylphenidate, anticholinergics, or amantadine) during the study or within 90 days prior to baseline have received treatment with dopamine blocking agents (including neuroleptic agents, antiemetic agents), dopamine-depleting agents (including reserpine or tetrabenazine) within 90 days prior to baseline do not consent to participate